PriceTargets.com logo

Phreesia - PHR Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $29.42
  • Forecasted Upside: 35.37%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$21.73 As of 12/6/2024 01:00 AM ET
▲ +0.6 (2.84%)

This chart shows the closing price for PHR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Phreesia Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PHR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PHR

Analyst Price Target is $29.42
▲ +35.37% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Phreesia in the last 3 months. The average price target is $29.42, with a high forecast of $34.00 and a low forecast of $23.00. The average price target represents a 35.37% upside from the last price of $21.73.

This chart shows the closing price for PHR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 12 investment analysts is to moderate buy stock in Phreesia. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/15/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/13/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/12/2023
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/11/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/9/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/7/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/6/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/6/2024

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/27/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$23.00 ➝ $23.00
9/9/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$27.00 ➝ $28.00
9/6/2024Truist FinancialBoost TargetBuy ➝ Buy$29.00 ➝ $31.00
9/6/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$31.00 ➝ $34.00
9/5/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$30.00 ➝ $30.00
9/5/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$23.00 ➝ $23.00
9/5/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$34.00 ➝ $34.00
9/5/2024DA DavidsonReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
9/5/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
8/30/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$30.00 ➝ $30.00
7/11/2024KeyCorpLower TargetOverweight ➝ Overweight$27.00 ➝ $25.00
7/1/2024Truist FinancialReiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
6/3/2024Truist FinancialLower TargetBuy ➝ Buy$35.00 ➝ $29.00
5/31/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$37.00 ➝ $34.00
5/31/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$30.00 ➝ $30.00
5/31/2024StephensReiterated RatingOverweight ➝ Overweight$28.00 ➝ $28.00
5/31/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
3/22/2024StephensReiterated RatingOverweight ➝ Overweight$28.00
3/21/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$23.00
3/21/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$28.00 ➝ $30.00
3/18/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$30.00 ➝ $31.00
3/15/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$36.00 ➝ $37.00
3/15/2024DA DavidsonReiterated RatingNeutral ➝ Neutral$32.00
3/15/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$28.00
3/15/2024Raymond JamesReiterated RatingOutperform ➝ Outperform$25.00 ➝ $30.00
3/15/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$17.00 ➝ $23.00
3/15/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$29.00
2/26/2024Truist FinancialInitiated CoverageBuy$35.00
1/18/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$29.00
1/17/2024DA DavidsonUpgradeNeutral ➝ Buy$30.00 ➝ $32.00
1/3/2024BarclaysInitiated CoverageOverweight$29.00
12/7/2023KeyCorpLower TargetOverweight ➝ Overweight$40.00 ➝ $30.00
12/7/2023Raymond JamesLower TargetOutperform ➝ Outperform$30.00 ➝ $25.00
12/6/2023Needham & Company LLCLower TargetBuy ➝ Buy$40.00 ➝ $29.00
12/6/2023JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$39.00 ➝ $28.00
9/12/2023Piper SandlerLower TargetOverweight ➝ Overweight$43.00 ➝ $40.00
9/11/2023Raymond JamesLower TargetOutperform ➝ Outperform$40.00 ➝ $30.00
9/7/2023William BlairReiterated RatingOutperform
9/7/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$46.00 ➝ $43.00
9/7/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$40.00
9/7/2023StephensReiterated RatingOverweight ➝ Overweight$37.00
9/7/2023Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$33.00 ➝ $29.00
9/7/2023CitigroupLower TargetBuy ➝ Buy$40.00 ➝ $37.00
9/7/2023Robert W. BairdLower Target$40.00 ➝ $39.00
9/1/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$46.00
8/15/2023StephensReiterated RatingOverweight ➝ Overweight$37.00
6/2/2023Robert W. BairdLower Target$41.00 ➝ $40.00
5/25/2023KeyCorpLower Target$45.00 ➝ $40.00
4/11/2023StephensInitiated CoverageOverweight$37.00
3/29/2023GuggenheimBoost TargetBuy$35.00 ➝ $40.00
3/23/2023DA DavidsonBoost TargetNeutral$28.00 ➝ $30.00
3/23/2023Royal Bank of CanadaBoost TargetSector Perform$26.00 ➝ $33.00
3/23/2023JMP SecuritiesBoost TargetOutperform$34.00 ➝ $39.00
2/2/2023KeyCorpBoost TargetOverweight$40.00 ➝ $45.00
1/25/2023Piper SandlerBoost TargetOverweight$37.00 ➝ $43.00
1/5/2023Leerink PartnersBoost TargetOutperform$34.00 ➝ $39.00
1/4/2023Needham & Company LLCBoost TargetBuy$35.00 ➝ $40.00
12/14/2022Robert W. BairdBoost Target$41.00
12/13/2022CitigroupUpgradeNeutral ➝ Buy$40.00
12/9/2022Royal Bank of CanadaBoost TargetSector Perform$22.00 ➝ $26.00
12/9/2022Piper SandlerBoost Target$33.00 ➝ $37.00
12/9/2022DA DavidsonBoost Target$25.00 ➝ $28.00
12/9/2022Leerink PartnersUpgradeMarket Perform ➝ Outperform$31.00 ➝ $34.00
12/9/2022CitigroupBoost Target$25.00 ➝ $28.00
10/12/2022DA DavidsonInitiated CoverageNeutral$25.00
9/15/2022KeyCorpInitiated CoverageOverweight$40.00
9/8/2022Canaccord Genuity GroupLower TargetBuy$37.00 ➝ $36.00
9/8/2022Royal Bank of CanadaBoost TargetSector Perform$20.00 ➝ $22.00
9/8/2022GuggenheimBoost TargetBuy$30.00 ➝ $35.00
9/8/2022CitigroupBoost Target$23.00 ➝ $25.00
9/8/2022Leerink PartnersBoost TargetMarket Perform$27.00 ➝ $31.00
6/14/2022Piper SandlerLower TargetOverweight$42.00 ➝ $32.00
6/6/2022Royal Bank of CanadaLower Target$29.00 ➝ $20.00
6/6/2022Raymond JamesLower Target$45.00 ➝ $34.00
6/3/2022GuggenheimLower TargetBuy$45.00 ➝ $30.00
6/3/2022Robert W. BairdLower TargetOutperform$51.00 ➝ $35.00
6/3/2022JMP SecuritiesLower TargetMarket Outperform$50.00 ➝ $34.00
6/3/2022CitigroupLower TargetNeutral$36.00 ➝ $23.00
6/3/2022Leerink PartnersLower TargetMarket Perform$29.00 ➝ $22.00
4/13/2022GuggenheimInitiated CoverageBuy$45.00
4/7/2022Royal Bank of CanadaLower TargetSector Perform$51.00 ➝ $29.00
4/4/2022Piper SandlerLower Target$54.00 ➝ $42.00
4/1/2022Raymond JamesLower TargetOutperform$55.00 ➝ $45.00
3/31/2022Canaccord Genuity GroupLower TargetBuy$81.00 ➝ $49.00
3/31/2022JPMorgan Chase & Co.Lower Target$51.00 ➝ $42.00
3/31/2022Leerink PartnersLower TargetMarket Perform$41.00 ➝ $29.00
3/31/2022Needham & Company LLCLower TargetBuy$65.00 ➝ $35.00
3/31/2022JMP SecuritiesLower TargetMarket Outperform$70.00 ➝ $50.00
3/31/2022CitigroupLower TargetNeutral$54.00 ➝ $36.00
1/6/2022Leerink PartnersDowngradeOutperform ➝ Market Perform$57.00 ➝ $41.00
12/14/2021Raymond JamesLower TargetOutperform ➝ Outperform$75.00 ➝ $55.00
12/14/2021Piper SandlerLower TargetOverweight ➝ Overweight$69.00 ➝ $54.00
12/10/2021CitigroupLower TargetNeutral ➝ Neutral$72.00 ➝ $54.00
12/10/2021Leerink PartnersLower TargetOutperform$75.00 ➝ $57.00
12/9/2021Needham & Company LLCLower TargetBuy ➝ Buy$81.00 ➝ $65.00
12/9/2021Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$60.00 ➝ $51.00
12/1/2021Jefferies Financial GroupInitiated CoverageBuy$70.00
9/7/2021Berenberg BankReiterated RatingBuy$75.00
9/3/2021Raymond JamesBoost TargetOutperform$65.00 ➝ $75.00
9/3/2021Robert W. BairdBoost TargetOutperform$62.00 ➝ $67.00
9/2/2021Royal Bank of CanadaBoost TargetSector Perform$51.00 ➝ $60.00
9/2/2021Needham & Company LLCBoost TargetBuy$70.00 ➝ $81.00
7/13/2021JMP SecuritiesInitiated CoverageOutperform$80.00
7/12/2021KeyCorpBoost TargetOverweight$70.00 ➝ $73.00
6/17/2021JPMorgan Chase & Co.Boost TargetOverweight$64.00 ➝ $68.00
6/8/2021Berenberg BankInitiated CoverageBuy$70.00
6/7/2021Robert W. BairdBoost TargetOutperform$60.00 ➝ $62.00
6/7/2021Piper SandlerBoost TargetOverweight$58.00 ➝ $63.50
6/6/2021Leerink PartnersReiterated RatingBuy
4/29/2021JPMorgan Chase & Co.Initiated CoverageOverweight
4/1/2021Leerink PartnersLower TargetOutperform$85.00 ➝ $75.00
4/1/2021Robert W. BairdInitiated CoverageOutperform$60.00
3/31/2021Piper SandlerReiterated RatingOverweight$56.00 ➝ $58.00
3/31/2021KeyCorpLower TargetOverweight$80.00 ➝ $70.00
1/14/2021Needham & Company LLCBoost TargetBuy$60.00 ➝ $70.00
12/14/2020Smith Barney CitigroupBoost Target$33.00 ➝ $59.00
12/10/2020Royal Bank of CanadaBoost TargetSector Perform$33.00 ➝ $51.00
12/10/2020DA DavidsonBoost TargetBuy$35.00 ➝ $70.00
12/10/2020Leerink PartnersBoost TargetOutperform$37.00 ➝ $62.00
12/9/2020Piper SandlerBoost TargetOverweight$35.00 ➝ $56.00
12/9/2020Needham & Company LLCBoost TargetBuy$44.00 ➝ $60.00
12/4/2020KeyCorpBoost TargetOverweight$37.00 ➝ $50.00
11/10/2020StephensInitiated CoverageOverweight$50.00
10/27/2020Needham & Company LLCInitiated CoverageBuy$44.00
10/23/2020Robert W. BairdBoost TargetPositive ➝ Outperform$32.00 ➝ $44.00
9/22/2020DA DavidsonInitiated CoverageBuy$35.00
9/10/2020Raymond JamesBoost TargetOutperform$35.00 ➝ $36.00
9/10/2020Leerink PartnersBoost TargetOutperform$31.00 ➝ $37.00
9/9/2020Piper SandlerBoost TargetOverweight$34.00 ➝ $35.00
9/3/2020Raymond JamesReiterated RatingBuy
7/14/2020CitigroupInitiated CoverageNeutral$32.00
6/10/2020Raymond JamesBoost TargetOutperform$30.00 ➝ $35.00
6/9/2020KeyCorpBoost TargetOverweight$34.00 ➝ $37.00
5/20/2020KeyCorpBoost TargetOverweight$25.00 ➝ $34.00
5/15/2020GuggenheimInitiated CoverageBuy$31.00
4/24/2020Raymond JamesLower TargetOutperform$33.00 ➝ $30.00
4/24/2020Robert W. BairdBoost TargetOutperform$26.00 ➝ $28.00
4/24/2020Wells Fargo & CompanyLower TargetOverweight$35.00 ➝ $30.00
4/20/2020Royal Bank of CanadaInitiated CoverageSector Perform$21.00
4/13/2020Leerink PartnersInitiated CoverageOutperform$24.00
4/8/2020Robert W. BairdLower TargetOutperform$31.00 ➝ $26.00
3/31/2020KeyCorpLower TargetOverweight$36.00 ➝ $25.00
1/30/2020KeyCorpInitiated CoverageOverweight$36.00
1/8/2020Cantor FitzgeraldInitiated CoverageOverweight$32.00
12/19/2019Raymond JamesInitiated CoverageOutperform$33.00
(Data available from 12/7/2019 forward)

News Sentiment Rating

1.12 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 12 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/11/2024
  • 8 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/10/2024
  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/10/2024
  • 13 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/9/2024
  • 7 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/8/2024
  • 9 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/8/2024
  • 11 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/7/2024
  • 12 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/7/2024

Current Sentiment

  • 12 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Phreesia logo
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.
Read More

Today's Range

Now: $21.73
Low: $21.09
High: $22.19

50 Day Range

MA: $20.28
Low: $18.04
High: $22.79

52 Week Range

Now: $21.73
Low: $17.07
High: $29.16

Volume

415,991 shs

Average Volume

380,498 shs

Market Capitalization

$1.26 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.98

Frequently Asked Questions

What sell-side analysts currently cover shares of Phreesia?

The following sell-side analysts have issued stock ratings on Phreesia in the last twelve months: Barclays PLC, Canaccord Genuity Group Inc., DA Davidson, JMP Securities, JPMorgan Chase & Co., KeyCorp, Needham & Company LLC, Raymond James, Robert W. Baird, Royal Bank of Canada, Stephens, and Truist Financial Co..
View the latest analyst ratings for PHR.

What is the current price target for Phreesia?

0 Wall Street analysts have set twelve-month price targets for Phreesia in the last year. Their average twelve-month price target is $29.42, suggesting a possible upside of 35.4%. Robert W. Baird has the highest price target set, predicting PHR will reach $34.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $23.00 for Phreesia in the next year.
View the latest price targets for PHR.

What is the current consensus analyst rating for Phreesia?

Phreesia currently has 1 hold rating and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for PHR.

What other companies compete with Phreesia?

Other companies that are similar to Phreesia include Nuvei, TriNet Group, Alight, Clarivate and DXC Technology. Learn More about companies similar to Phreesia.

How do I contact Phreesia's investor relations team?

Phreesia's physical mailing address is 432 Park Avenue South 12th Floor, New York NY, 10016. The company's listed phone number is (888) 654-7473 and its investor relations email address is [email protected]. The official website for Phreesia is www.phreesia.com. Learn More about contacing Phreesia investor relations.